American Journal of Cardiology
Volume 103, Issue 11 , Pages 1518-1524 , 1 June 2009

Association Between Mortality and Persistent Use of Beta Blockers and Angiotensin-Converting Enzyme Inhibitors in Patients With Left Ventricular Systolic Dysfunction and Coronary Artery Disease

Received 4 December 2008 ,Revised 31 January 2009 ,Accepted 31 January 2009.

References 

  1. Phillips C, Kashani A, Ko D, Francis G, Krumholz H. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction. Arch Intern Med. 2007;167:1930–1936
  2. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. 2nd ed.. New York: John Wiley and Sons; 1999;
  3. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to Cox regression model. Stat Med. 1992;11:2093–2109
  4. Stone CJ, Koo C. Additive splines in statistics. Proc Stat Comp Sect Am Statist Assoc. 1985;45–48
  5. Lin J, Zhang D, Davidian M. Smoothing spline-based score tests for proportional hazards models. Biometrics. 2006;62:803–812
  6. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  7. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9–13
  8. Packer M, Coats A, Fowler M, Katus HA, Krum H, Mohacsi P, et al Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  9. Hunt SA American College of Cardiology American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult (A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)). J Am Coll Cardiol. 2005;46:e1–e82
  10. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–e2
  11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435
  12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302
  13. Young J, Dunlap M, Pfeffer M, Probstfield JL, Cohen-Solal A, Dietz R, et al Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results from CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110:2618–2626
  14. White H, Aylward P, Huang Z, Dalby AJ, Weaver WD, Barvik S, et al Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. 2005;112:3391–3399
  15. Lenzen M, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26:2706–2713
  16. DeBusk R, Miller N, Parker K, Bandura A, Kraemer HC, Cher DJ, et al. Care management for low-risk patients with heart failure: a randomized controlled trial. Ann Intern Med. 2004;141:606–613
  17. Philbin EF. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. J Gen Intern Med. 1999;14:130–135
  18. Phillips C, Wright S, Kern D, Singa R, Shepperd S, Rubin H. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291:1358–1367
  19. Tierney W, Overhage M, Murray M, Harris LE, Zhou XH, Eckert GJ, et al. Effects of computerized guidelines for managing heart disease in primary care. J Gen Intern Med. 2003;18:967–976
  20. Whellan D, Gaulden L, Gattis W, Granger B, Russell SD, Blazing MA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med. 2001;161:2223–2228
  21. Koshman S, Charrois T, Simpson S, McAlister F, Tsuyuki R. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168:687–694
  22. Ansari M, Shlipak M, Heidenreich P, Van Ostaeyen D, Pohl EC, Browner WS, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation. 2003;107:2799–2804
  23. Bonet S, Agusti A, Arnau J, Vidal X, Diogène E, Galve E, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and nonvasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621–627
  24. Go A, Yang J, Gurwitz J, Hsu J, Lane K, Platt R. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure. Am J Cardiol. 2007;100:690–696
  25. Fonarow G, Abraham W, Albert N, Stough WG, Gheorghiade M, Greenberg BH, et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;153:82.e1–82.e11
  26. Pfeffer M, Swedberg K, Granger C, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  27. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112:2426–2435
  28. Jong P, Yusuf S, Rousseau M, Ahn S, Bangdiwala S. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843–1848

 This work was supported in part by Grant U18HS10548 from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, Rockville, Maryland.

PII: S0002-9149(09)00531-1

doi: 10.1016/j.amjcard.2009.01.363

American Journal of Cardiology
Volume 103, Issue 11 , Pages 1518-1524 , 1 June 2009

Article Tools

* Image Usage & Resolution